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TSObjectives: The aim of the present study was to evaluate the feasibility and diagnostic
value of repeat mediastinoscopy as part of the response-evaluation protocol of 2 phase
II multimodality studies for either stage IIIA/B non–small cell lung cancer or small
cell lung cancer.
Methods: From January 1991 through December 1998, 104 patients (79 men and 25
women) with stage IIIA/B non–small cell lung cancer (84 patients) or small cell lung
cancer (17 patients) were enrolled in 2 different multimodality trials and underwent
remediastinoscopy after induction chemoradiotherapy. The median age was 56 years
(range, 34–72 years). Sensitivity, specificity, accuracy, and predictive values of reme-
diastinoscopy were calculated by using standard definitions.
Results: Remediastinoscopy was feasible in 98% of cases. Mortality was nil, and mor-
bidity very low (1.9%). Lymph node downstaging (N0) was observed in 84 patients,
persisting N2 disease was observed in 15 patients, and N3 disease was observed in 5
patients. Sensitivity was 61%, specificity was 100%, and accuracy was 88%. Positive
predictive and negative predictive values reached 100% and 85%, respectively.
According to the results of remediastinoscopy, 81 patients underwent surgical inter-
vention, 3 refused the operation, and an unnecessary thoracotomy could be avoided in
the remaining 20.
Conclusions: Remediastinoscopy provides a histologic proof of mediastinal down-
staging with high diagnostic accuracy, is technically feasible with low morbidity,
and still remains a valuable tool, even in an era of highly sophisticated imaging and
endoscopic procedures. Persisting nodal disease at repeat mediastinoscopy carries
a poor survival in the majority of cases because of occult metastases, so that indication
for surgical intervention in such an unfavorable group of patients should be evaluated
very carefully.
T
he prognosis of locoregionally advanced lung cancer is overall poor, with 5-
year survival rates ranging from 5% to a maximum of 15%. With the introduc-
tion of multimodal treatment protocols, including induction chemotherapy,
radiotherapy, and surgical intervention, an improvement of the expected survival
has been observed in non–small cell lung cancer (NSCLC) and in small series of
selected patients with small cell lung cancer (SCLC).1-6
In multimodality approaches including surgical intervention, an accurate response
evaluation after induction therapy continues to represent a major diagnostic challenge:
it should define which patients benefit from surgical treatment and state whether the
technical and prognostic operability are given. On the other hand, the indication of
surgical intervention in nonresponders should be strongly restricted because in
most cases resection of primary tumor does not improve survival.
Standard staging procedures, such as computed tomography (CT) and magnetic
resonance imaging, are of limited value in the response evaluation after induction
therapy because of their intrinsic inability to differentiate between viable tumor and
necrosis or scarring on a morphologic basis, thus resulting in low accuracy to stage
either the primary tumor or mediastinal lymph nodes.7,8 Modern methods (eg,
Earn CME credits at http://
cme.ctsnetjournals.org
From the Department of Thoracic Surgery
and Endoscopy,a Ruhrlandklinik, Essen,
Germany, and the Department of Thoracic
Surgery,b Klinikum St Georg, Ostercappeln,
Germany.
Received for publication June 10, 2007;
revisions received June 10, 2007; accepted
for publication July 30, 2007.
Address for reprints: Alessandro Marra, MD,
Department of Thoracic Surgery and En-
doscopy, Ruhrlandklinik, Tu¨schener Weg
40, D-45239 Essen, Germany (E-mail:
alexmarra@yahoo.it).
J Thorac Cardiovasc Surg 2008;135:843-9
0022-5223/$34.00
Copyright  2008 by The American Asso-
ciation for Thoracic Surgery
doi:10.1016/j.jtcvs.2007.07.073The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 4 843
General Thoracic Surgery Marra et al
G
TSAbbreviations and Acronyms
CT 5 computed tomography
EUS 5 endoesophageal ultrasonography
FNA 5 fine-needle aspiration
NSCLC 5 non–small cell lung cancer
PET 5 positron emission tomography
SCLC 5 small cell lung cancer
positron emission tomography [PET], PET/CT fusion imag-
ing, endoesophageal ultrasonography [EUS] with fine-needle
aspiration biopsy [FNA], and endobronchial ultrasonography
with FNA) are gaining a primary role in both staging and
restaging of lung cancer by coupling morphologic features
with functional or cytohistologic information. This results
in potentially improved accuracy,9-14 but these techniques
are costly, are not available everywhere, and have a reliability
that is still under investigation.
Thus far, because mediastinoscopy still constitutes the
gold standard for staging the mediastinum before treatment,
some reports suggest that repeat mediastinoscopy is a safe
and accurate tool for response evaluation of mediastinal
lymph nodes metastasis after induction therapy.15-19
The aim of the present study was to evaluate retrospec-
tively the diagnostic value and feasibility of repeat mediasti-
noscopy as part of our phase II study of multimodality
protocols for treating either stage IIIA/B NSCLC2 or SCLC.3
Materials and Methods
From January 1991 through December 1998, 104 patients (79 men
and 25 women) with stage IIIA/B NSCLC or SCLC were enrolled
in 2 different prospective multimodality trials at the Ruhrlandklinik,
Essen, Germany. Inclusion criteria, study design, and treatment
protocols have been described in detail elsewhere.2,3 After a complete
staging including mediastinoscopy, patients were treated with induc-
tion chemoradiotherapy and successively underwent remediastino-
scopy. The median age was 56 years (range, 34–72 years). The
clinical characteristics of the study population are listed in Table 1.
All but 5 patients had N2 or N3 disease at first mediastinoscopy. In
the NSCLC study the first 5 patients with negative mediastinoscopy
results for stage IIIB (T4) disease underwent remediastinoscopy as
part of the restaging procedures. Because the negative nodal status
was confirmed in all cases, no further second look at the mediastinum
was planned in the successive patients of this subgroup.
NSCLC Study
Patients were planned for 3 courses of chemotherapy with 60 mg/m2
cisplatin administered intravenously on days 1 and 7 (or day 8) and
150 mg/m2 etoposide administered intravenously on days 3, 4, and
5. Cycles were repeated every 22 days. Normally, during the tenth
week of treatment, concurrent chemoradiotherapy was started,
combining twice-daily hyperfractionated accelerated radiotherapy
(1.5 Gy per fraction more than 6 hours apart for 5 days a week to
a total dose of 45 Gy over a period of 3 weeks) with one course844 The Journal of Thoracic and Cardiovascular Surgery c Aprof chemotherapy that consisted of 50 mg/m2 cisplatin administered
intravenously on days 2 and 9 (after the start of radiotherapy) and
100 mg/m2 etoposide on days 4, 5, and 6. Since 1993, because
a significant number of isolated relapses in the brain were noted
among the first patients of the NSCLC study, all subsequent patients
were offered elective cranial irradiation.
SCLC Study
Patients with stage IIB/IIIA disease were given 3 cycles of cisplatin/
etoposide, and during week 10, concurrent chemoradiotherapy was
started, combining twice-daily hyperfractionated accelerated radio-
therapy with one cycle of cisplatin/etoposide. Induction chemother-
apy consisted of 50 mg/m2 cisplatin as a 1-hour infusion on days 1
and 7 (or day 8 if an outpatient). Etoposide was administered at 170
mg/m2 as a 1-hour infusion on days 3, 4, and 5. Radiotherapy was
administered at a total dose of 45 Gy to the primary tumor and the
mediastinal nodes in 2 daily fractions of 1.5 Gy within 3 weeks.
The minimum time interval between fractions was 6 hours. The
technique of radiation delivery was the same as in our NSCLC
trimodality trial.2 Simultaneous chemotherapy was started on day
2 of radiation (50 mg/m2 cisplatin on days 2 and 9 and 100 mg/m2
etoposide on days 4, 5, and 6).
Three weeks after the completion of radiotherapy, a complete
restaging, including repeat mediastinoscopy, was routinely per-
formed, and depending on the response status, this was followed
by definitive surgical intervention 4 to 6 weeks after the end of
radiation therapy.
TABLE 1. Clinical characteristics of lung cancer patients
before remediastinoscopy
Clinical features No. Percentage
Total no. of patients 104 100





Squamous cell carcinoma 38 36.5
Adenocarcinoma 36 34.6
Large cell carcinoma 11 10.6
Small cell carcinoma 17 16.3
Neuroendocrine (carcinoid) 1 1.0








N0 (T4) 5 4.8
N2 74 71.2
N3 25 24.0
NSCLC, Non–small cell lung cancer; SCLC, small cell lung cancer; RUL, right
upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper
lobe; LLL, left lower lobe.il 2008
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surgeon who performed the first examination; those patients in
whom mediastinoscopy had to be carried out in a referring hospital
were operated on by one of the senior surgeons at our institution.
The operative technique of remediastinoscopy differed slightly
from that of the first procedure. After excision of the existing scar,
dissection was carried out on the midline to expose the trachea. After
incision of the pretracheal fascia, the mediastinum was bluntly
accessed, sharply accessed, or both along the mediastinoscopic
route until a left or right paratracheal tunnel was created. In case
of diffuse peritracheal adhesions, a mediastinoscope was inserted
early through the cervicotomy to allow further dissection with the
regular coagulation cannula. In case of unclear anatomic appear-
ance, before taking a biopsy specimen, the target area was sounded
with a fine needle to avoid damage of a great vessel. Stations 2R, 4R,
2L, 4L, 3, and 7 according to the Regional Lymph Node Classifica-
tion for Lung Cancer Staging20 were systematically explored. Addi-
tionally, a bronchoscopy with biopsy specimens of prospective
bronchial resection margins was performed.
Eligibility criteria for surgical resection were negative or ‘‘min-
imally positive’’ remediastinoscopy results (microscopic residual
tumor in a single ipsilateral lymph node station), absence of distant
metastases, cardiopulmonary operability, and provision of informed
consent. At thoracotomy, depending on the dimension and location
of the primary tumor, a variable amount of lung tissue was resected;
in all cases a systematic lymphadenectomy of the interlobar, hilar,
and ipsilateral mediastinal lymph node stations was performed
(for right-sided thoracotomies, stations 2R, 3, 4R, 7, 8R, 9R, 10R,
and 11R; for left-sided thoracotomies, stations 3, 4L, 5, 6, 7, 8L,
9L, 10L, and 11L).
The sensitivity, specificity, accuracy, and predictive values of
remediastinoscopy were calculated by using standard definitions.
Statistical analysis was carried out with a software package (Statis-
tical Program for the Social Sciences, release 10.0.7; SPSS, Inc,
Chicago, Ill). Cross-tabulations with the Pearson c2 test were used
for group comparison when appropriate.
Results
At first mediastinoscopy, the number of lymph node stations
undergoing biopsy was 453 of the potential 624 (biopsy rate,
73%). When excluding the pretracheal station (station 3),
which was not always anatomically represented, the biopsy
rate was 84% (437/520 stations). At remediastinoscopy,
corresponding values, with and without station 3, were 53%
(331/624) and 61% (315/520), respectively. Because of ex-
tensive fibrous adhesions and scar tissue, in 2 patients repeat
mediastinoscopy was attempted but should have been stopped
without taking biopsy material. Thus a pathologic restaging of
mediastinum was possible in 98% (102/104) of patients.
The distribution of the findings at first mediastinoscopy
and remediastinoscopy, according to the lymph node station,
is shown in Figure 1. It is noteworthy that the biopsy rate in
stations 2R, 4R, 4L, and 7 at first mediastinoscopy ranged
from 88% to 98%, whereas in station 2L it decreased to
56%. Similarly, the biopsy rate in the former stations at
remediastinoscopy ranged from 63% to 84% and was veryThe Journal of Tholow (21%) in the left upper paratracheal region to avoid
a lesion of the left recurrent laryngeal nerve.
At first mediastinal exploration, 199 stations undergoing
biopsy showed positive results, and 254 showed negative
results (ratio, 0.78); at the second look, tumor was detected
in 38 stations, whereas 293 were tumor free (ratio, 0.13).
Among the negative samples after induction therapy, 28
(10%) showed only scarred nonlymphatic tissue, and 5
(2%) showed necrotic material.
Primary staging revealed N2 disease in 74 (71%) cases,
N3 disease in 25 (24%) cases, and N0 disease with a nonre-
sectable T4 tumor in 5 (5%) cases. These first 5 study patients
Figure 1. Distribution of pathologic findings of mediastinoscopy
(A) and remediastinoscopy (B) according to lymph node station.racic and Cardiovascular Surgery c Volume 135, Number 4 845
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scopy as planned in the study protocol. Because the N0 status
was confirmed at the mediastinal second look in all cases,
subsequent patients with T4 N0 disease did not receive any
invasive mediastinal staging after induction treatment. At re-
peat mediastinoscopy, 15 (14%) patients had N2 disease, 5
(5%) had N3 disease, and 84 (81%) had no evidence of lymph
node metastasis.
According to the results of restaging after induction ther-
apy, a prognostically oriented treatment was planned. Of the
84 patients with N0 disease, 81 underwent surgical interven-
tion; of the remaining patients, 2 refused operations and
received definitive radiotherapy, and in 1 case magnetic res-
onance imaging was able to detect liver metastases after a sus-
picious abdominal CT scan and ultrasonographic analysis.
This patient was offered palliative second-line chemother-
apy. All patients with N3 disease and the 9 patients with mul-
tiple-station N2 disease were treated with definitive radiation
therapy, as were as 3 patients with single-station N2 disease
who refused surgical intervention or were medically inoper-
able. The remaining 3 patients with single-station N2 disease
were fit for surgical intervention and underwent operations.
After thoracotomy, staging was completed in all patients:
65 (62%) of them had N0 or N1 tumors, 33 (32%) had N2 tu-
mors, and 6 (6%) had N3 tumors. Regarding the patients with
N2 disease, in the 3 patients who underwent surgical inter-
vention, open lymphadenectomy confirmed the findings of
remediastinoscopy (true positive); in 18 patients ipsilateral
mediastinal lymph node metastases were detected despite
negative remediastinoscopy results, 12 of which were inside
the anatomic boundaries of the cervical mediastinoscopy
(false-negative result) and 6 of which were outside the
boundaries (eg, stations 3a, 8, and 9; true-negative result).
TABLE 2. Diagnostic accuracy of remediastinoscopy:
Subgroup differentiation according to the definitive nodal
status at thoracotomy (n 5 104)
Finding n Nodal status n Difference
True-negative result 71 N0–N1 65 P 5 .0000
N2* 6
N3 0
False-negative result 13 N0–N1 2
N2 12
N3 1








*Positive mediastinal lymph nodes beyond the anatomic boundaries of
cervical mediastinoscopy.846 The Journal of Thoracic and Cardiovascular Surgery c ApriOne patient with a negative remediastinoscopy result had
N3 disease at thoracotomy (false-negative result).
In summary, remediastinoscopy had a sensitivity of 61%,
a specificity of 100%, and an accuracy of 88%; positive and
negative predictive values were 100% and 85%, respectively.
The diagnostic value of remediastinoscopy is analyzed in
detail in Tables 2 and 3.
Analysis of cases with false-negative results showed 20
false tumor-free biopsy stations in 12 patients: missed diag-
noses were found most frequently in the left lower paratra-
cheal (7 cases, 58%) and subcarinal (7 cases, 58%) regions;
right upper paratracheal (3 cases, 25%), right lower paratra-
cheal (2 cases, 17%), and left upper paratracheal (one case,
8%) regions also had false-negative biopsy findings. More
than 1 false-negative station was found in 4 (33%) patients.
First mediastinoscopy was complicated by recurrent nerve
palsy with hoarseness in 3 (2.9%) patients, atrial fibrillation
in 2 (1.9%) patients, and intraoperative bleeding controlled
by packing in 1 (1%) patient. At remediastinoscopy, the
only 2 (1.9%) observed adverse events were lesions of the
left recurrent nerve.
TABLE 3. Diagnostic accuracy of remediastinoscopy:
Subgroup differentiation according to the lymph node
station
Lymph node station Finding n Accuracy*
























NE, Not evaluable. *Accuracy was calculated as follows: ðTrue2 positive
result 1 True2negative resultÞ=ðTrue2positive result 1 True2 negative
result 1 False2negative result 1 No biopsyÞ: yIn most cases no lymph
nodes were anatomically present in this station.l 2008
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The results of the present study show that remediastinoscopy
can be a safe and accurate tool for restaging lung cancer after
induction therapy, with sensitivity, specificity, and accuracy
values of 61%, 100%, and 88%, respectively. Two of us (GS
and LH), in a previous analysis, have already reported on
a greater series of repeat mediastinoscopies performed over
a longer time interval,21 but the present study was planned
to focus only on a ‘‘pure’’ population of patients enrolled
in 2 published prospective trials on lung cancer treated with
multimodality therapy to avoid selection bias related to inho-
mogeneous treatment or long-time dispersion factors.
The importance of downstaging of mediastinal lymph
nodes after induction therapy for stage IIIA (N2) or IIIB
(N3) NSCLC has been underlined by several studies. In
fact, the clearing of mediastinum represents a major prognos-
ticator, with 5-year survival rates of about 40% for patients
without residual nodal disease in contrast to 5% to 10% for
patients with persistent positive nodal status.1,4-6,22 In the
Southwest Oncology Group phase II Study 8805, 126 eligi-
ble patients with stage IIIA (N2) or IIIB NSCLC underwent
concurrent cisplatin/etoposide plus chest radiotherapy, fol-
lowed by surgical intervention; response evaluation after
induction did not include remediastinoscopy. In the subset
of 74 patients who originally had positive mediastinal lymph
nodes and then underwent complete resection, the median
survival time and 3-year survival for uninvolved versus
involved nodes at surgical intervention were 30 versus 9
months and 41% versus 11%, respectively (P 5 .003).1
Bueno and coworkers4 reviewed the long-term outcomes of
103 patients with stage IIIA N2-positive NSCLC treated
with neoadjuvant therapy (platinum-based chemotherapy,
radiotherapy, or chemoradiation) and surgical resection. All
patients were restaged with chest CT scans before their oper-
ations. Twenty-nine patients downstaged to N0 disease had
a 5-year survival of 35.8% and a median survival of 21.3
months; 74 patients with persistent tumor in their lymph
nodes (N1 or N2) did significantly worse, with a 9% 5-year
survival rate and a 15.9-month median survival (P 5 .023).
The Swiss Group for Clinical Cancer Research designed
a multicenter phase II trial in which 90 eligible patients
were treated with induction chemotherapy with the sub-
stances cisplatin/docetaxel and subsequent surgical resection.
The most powerful prognostic factor identified was the clear-
ance of mediastinal lymph nodes: patients with persistent
nodal disease had a poor 3-year survival rate of 11% in con-
trast to a 73% survival rate at 3 years for patients with nodal
downstaging (P 5 .0003).6 De Waele and colleagues22 re-
ported on 32 patients treated with induction chemotherapy
or chemoradiotherapy for locally advanced NSCLC and re-
staged by means of remediastinoscopy: the 5-year survival
rate of the group with negative remediastinoscopy results
was 42%, whereas the combined group with positive orThe Journal of Thofalse-negative remediastinoscopy results had a 14% 5-year
survival rate (P5 .012). This evidence supports the assump-
tion that principally patients with cleared mediastinal lymph
nodes can benefit from surgical intervention after induction
therapy. On the other hand, patients with persistent nodal dis-
ease are at high risk of distant metastases, and surgical resec-
tion of the primary tumor probably adds little advantage in
terms of prognosis and relapse-free survival. Therefore before
planning any surgical option after induction therapy, an accu-
rate response evaluation focused on nodal status should be
performed.
CT scanning has shown limited value in primary staging
of lung cancer, particularly in the detection of mediastinal
lymph node metastases. Dillemans and associates,7 setting
a cutoff of 1.5 cm of major diameter for considering a lymph
node pathologic, observed among 569 CT examinations for
lung cancer staging a sensitivity of 69%, a specificity of
71%, and an accuracy of 71%. In the restaging of the medi-
astinum after induction therapy, the accuracy of CT scans
decreases to 58%, with a sensitivity of 41% and a specificity
of 75%, as stated in a recent study.8
PET scanning with 18F-2-fluoro-2-deoxy-D-glucose has
gained an accepted value as an initial staging investigation
in lung cancer. The median sensitivity and specificity of
PET scanning with 18F-2-fluoro-2-deoxy-D-glucose for
identifying mediastinal lymph node involvement was 85%
and 90%, respectively, in the meta-analysis of Gould and
coworkers.9 Poettgen and associates13 investigated the value
of combined PET/CT in the restaging of 50 patients with
locally advanced NSCLC treated with induction chemother-
apy and combined chemoradiation. Variables from the PET/
CT studies (eg, lesion volume and corrected maximum stan-
dardized glucose uptake values) were correlated with histo-
pathologic response and time of failure. In the evaluation
of mediastinal lymph nodes, corrected maximum standard-
ized glucose uptake values after therapy predicted any
ypN0 status with a sensitivity and specificity of 73% and
89%, respectively (P 5 .0005).
Recently, the minimally invasive technique of transeso-
phageal EUS-FNA has become clinically available for the
analysis of mediastinal lymph nodes. Because the procedure
showed a high diagnostic accuracy (89% to 95%) for the
analysis of mediastinal lymph nodes in the primary staging
of lung cancer, Annema and coworkers14 investigated its
diagnostic yield in the restaging setting. Nineteen consecu-
tive patients with NSCLC and proved ipsilateral lymph
node metastases (N2 disease) who had been treated with
induction chemotherapy underwent mediastinal restaging
with EUS-FNA. In 2 patients no biopsy specimens were
taken, and in 8 patients a single lymph node station and in
9 patients 2 different lymph node stations underwent biopsy.
In 5 (26%) cases of nondiagnostic EUS-FNA, restaging
mediastinoscopy (remediastinoscopy in 2 cases) was re-
quired to assess the lymph node status. The sensitivity,racic and Cardiovascular Surgery c Volume 135, Number 4 847
General Thoracic Surgery Marra et al
G
TSspecificity, positive predictive value, negative predictive
value, and diagnostic accuracy of EUS-FNA in this group
of patients was 75%, 100%, 100%, 67%, and 83%, respec-
tively.
In a recently published prospective trial of patients with
mediastinoscopy-proved N2 disease, response evaluation
after induction chemoradiotherapy was based on CT, PET/
CT, and EUS-FNA. Ninety-three patients had their lymph
nodes pathologically restaged. The accuracy of repeat PET/
CT was superior to that of repeat CT for restaging at all path-
ologic stages (P 5 .03) and best for complete responders
(92%) and those with stage I disease (89%); however, it
decreased to only 69% for patients with persistent N2 dis-
ease. False-negative and false-positive results of restaging
PET/CT were as high as 20% and 25%, respectively. Thus
the authors advocated rebiopsy of suspected lymph nodes
in PET/CT as mandatory.10
Remediastinoscopy is generally considered by most tho-
racic surgeons as a hazardous and unsafe procedure, espe-
cially after induction treatment including radiotherapy.
However, many reports of authors who perform repeat surgi-
cal exploration of mediastinum as a routine part of multimo-
dality protocols suggest remediastinoscopy to be a safe and
accurate tool to exclude residual nodal disease after induction
treatment, as well as to avoid unnecessary thoracotomy in
patients with expected poor prognosis. Meersschaut and col-
leagues15 reviewed their experience with 140 repeat media-
stinoscopies in the assessment of new or recurrent lung
cancer. Because of adhesions, 18% of procedures had to be
considered incomplete. Sensitivity was 74%, and accuracy
was 94%. There was neither mortality nor major complica-
tions requiring interventional therapy. In the series reported
by Pauwels and associates,17 remediastinoscopy was feasible
in all patients without mortality and with a mild morbidity
(2/27 patients, 7%). Van Schil and colleagues,18 in their se-
ries of 27 neoadjuvant-treated patients, reported a sensitivity
of 73%, a specificity of 100%, and an accuracy of 85%. Four
cases with false-negative results were encountered, of which
3 occurred in the subcarinal lymph nodes.
Remediastinoscopy as a restaging procedure for recurrent
or second primary lung neoplasm after induction therapy for
locoregionally advanced lung cancer or after inadequate first
mediastinoscopy was analyzed by 2 of us (GS and LH) in
a previous report. Among 279 procedures over a long time
period, no perioperative deaths were observed, and only 7
(2.5%) patients had minor complications. Because of insepa-
rable adhesions, repeat mediastinoscopy was not possible in
5 (1.7%) cases. Sensitivity and accuracy were 74% and
92.5%, respectively. Of interest, 5-year survival of the patient
group with persistent nodal disease after induction chemora-
diotherapy was a disappointing 5% compared with 36.6% for
the responder (N0) group.21 In terms of feasibility and safety,
the present series confirms that repeat mediastinoscopy can
be performed with an acceptable operative risk (nil mortality848 The Journal of Thoracic and Cardiovascular Surgery c Aprand 2% morbidity) with high diagnostic yield in the vast
majority (98%) of patients. The importance of learning
from our own experience was pointed out by Rami–Porta
and cowerkers.8,19 In their first 24 patients undergoing redo
mediastinoscopy after induction chemotherapy for N2 bron-
chogenic carcinoma, sensitivity was 70%, and accuracy was
80%. In the following 24 patients, the values increased to
83% and 91%, respectively.
The results of our study do not differ significantly from
those of the literature: sensitivity with a 61% value was
slightly lower, but accuracy resulted as high as 88% and con-
firmed remediastinoscopy to be a valuable tool in the restaging
process. According to the lymph node station, we observed
most false-negative biopsy results in the left lower paratra-
cheal and subcarinal regions, which are the most hazardous
and difficult to explore during remediastinoscopy because of
the higher risk of laryngeal recurrent nerve and vessel lesions.
With regard to the difficult issue of restaging the medias-
tinum after induction treatment for lung cancer, remediastino-
scopy provided satisfactory accuracy in the majority of
reports. However, a recent study of the Leuven Lung Cancer
Group on 30 patients with stage IIIA N2 NSCLC treated with
induction chemotherapy reported a disappointing low sensi-
tivity and accuracy of remediastinoscopy compared with
that of integrated PET/CT (29% vs 77% [P , .0001] and
60% vs 83% [P 5 .012], respectively). These unexpected
results provoked some comments by thoracic surgeons who
have extensive experience with the procedure. Among the
possible causes for the poor diagnostic yields of remediasti-
noscopy in the Leuven experience have been advocated the
use of a large videomediastinoscope instead of the classical
instrument, the inadequate re-exploration of the subcarinal
station in two thirds of cases (in which persistent nodal
disease was found in 50% of cases at thoracotomy), and an
extensive examination at the first procedure resulting in
more dense adhesions.11,23-25
In conclusion, a precise response evaluation focused on
mediastinal lymph node status is mandatory to select patients
with locoregionally advanced lung cancer after induction
therapy for further prognostically oriented treatment.
PET scanning, particularly when integrated with CT
scanning, allows better restaging accuracy compared with
CT scanning alone but is expensive and not available
everywhere.
EUS-FNA can reach high accuracy in the primary staging
of lung cancer under the condition that only suspicious lymph
nodes on CT or PET scans are targeted; a systematic explo-
ration of the mediastinum is usually not included. Thereafter,
its value in the restaging setting is not adequately defined and
requires further investigation.
Remediastinoscopy provides a histologic proof of medias-
tinal downstaging with high diagnostic accuracy, in experi-
enced hands is technically feasible with low morbidity, and
still remains a valuable tool even in an era of highlyil 2008
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nodal disease at repeat mediastinoscopy carries in most cases
a poor survival caused by occult metastases, so that indica-
tion for surgical intervention in such an unfavorable group
of patients should be evaluated very carefully.
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